Alpelisib and Oxycodone and Ibuprofen
Determining the interaction of Alpelisib and Oxycodone and Ibuprofen and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with alpelisib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C9, such as warfarin. The proposed mechanism, based on in vitro data, is increased clearance due to alpelisib-mediated induction of CYP450 2C9. MANAGEMENT: Patient monitoring is recommended if alpelisib is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when alpelisib is prescribed in combination with drugs that are CYP450 2C9 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever alpelisib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2C9-inducing activity may also be considered. References "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.
Professional:MONITOR: Coadministration with alpelisib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C9, such as warfarin. The proposed mechanism, based on in vitro data, is increased clearance due to alpelisib-mediated induction of CYP450 2C9.
MANAGEMENT: Patient monitoring is recommended if alpelisib is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when alpelisib is prescribed in combination with drugs that are CYP450 2C9 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever alpelisib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2C9-inducing activity may also be considered.
- "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: ibuprofen / oxycodone
Brand name: Combunox
Synonyms: Ibuprofen and oxycodone
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Alpelisib-Oxycodone and naloxone
- Alpelisib-Oxycodone and naltrexone
- Alpelisib-Oxycodone Capsules
- Alpelisib-Oxycodone Capsules and Tablets
- Alpelisib-Oxycodone Concentrate
- Alpelisib-Oxycodone ER
- Oxycodone and Ibuprofen-Alph-E
- Oxycodone and Ibuprofen-Alph-E-Mixed
- Oxycodone and Ibuprofen-Alph-E-Mixed 1000
- Oxycodone and Ibuprofen-Alpha Lipoic Acid
- Oxycodone and Ibuprofen-Alpha-E
- Oxycodone and Ibuprofen-Alphagan P